PRINCETON, N.J., Nov. 11, 2024 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, is proud to announce ...
VUEWAY ® injection, a macrocyclic gadolinium-based contrast agent (GBCA), offers effective contrast enhancement at half the gadolinium (Gd) dose (0.05 mmol/kg) compared to other macrocyclic GBCAs for ...
PRINCETON, N.J., Nov. 11, 2024 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, is proud to announce ...
The benefit-risk ratio of Vueway considered positive in children from birthMILAN, Dec. 19, 2025 /PRNewswire/ -- Bracco Imaging S.p.A., a global leader in diagnostic imaging, announces that on ...
The PROMISE study was a prospective, multinational, crossover (within-patient), double-blind comparison of the safety and efficacy of 0.05 mmol/kg gadopiclenol (VUEWAY) with 0.1 mmol/kg gadobutrol ...
Bracco Imaging S.p.A., a global leader in diagnostic imaging, announces that on 11 December 2025 the Committee for Medicinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback